The same study revealed that PACAP-38 induced mild headache in healthy individuals.12 Furthermore, recent phase II trial data demonstrated the effectiveness of a mAb against PACAP signalling for migraine prevention.13 Considering the common occurrence of migraine-like headache in people with PTH and our finding of hypersensitivity to PACAP-38 in this patient population, blocking PACAP-38 effects might serve as a mechanism-based treatment option for PTH. The gene discussed is ADCYAP1; the disease is migraine disorder.